These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1226 related items for PubMed ID: 24636263

  • 1. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F, Takahashi F, Murakami A, Kobayashi I, Kato M, Shukuya T, Tajima K, Shimada N, Takahashi K.
    Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
    [Abstract] [Full Text] [Related]

  • 2. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [Abstract] [Full Text] [Related]

  • 3. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K, Yuan Q.
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Uramoto H, Yamada T, Yano S, Kondo N, Hasegawa S, Tanaka F.
    Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
    [Abstract] [Full Text] [Related]

  • 5. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
    Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, Yatabe Y, Sekido Y, Mitsudomi T.
    J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
    [Abstract] [Full Text] [Related]

  • 6. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J, Wang J, Zeng Y, Zhang X, Hu Q, Zheng J, Chen B, Xie B, Zhang WM.
    Oncotarget; 2015 Dec 29; 6(42):44332-45. PubMed ID: 26554308
    [Abstract] [Full Text] [Related]

  • 7. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M, He CS, Wei SH, Zhang L.
    Eur J Cancer; 2013 Nov 29; 49(16):3559-72. PubMed ID: 23916913
    [Abstract] [Full Text] [Related]

  • 8. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
    Yamamoto C, Basaki Y, Kawahara A, Nakashima K, Kage M, Izumi H, Kohno K, Uramoto H, Yasumoto K, Kuwano M, Ono M.
    Cancer Res; 2010 Nov 01; 70(21):8715-25. PubMed ID: 20959484
    [Abstract] [Full Text] [Related]

  • 9. XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
    Pietanza MC, Lynch TJ, Lara PN, Cho J, Yanagihara RH, Vrindavanam N, Chowhan NM, Gadgeel SM, Pennell NA, Funke R, Mitchell B, Wakelee HA, Miller VA.
    J Thorac Oncol; 2012 Jan 01; 7(1):219-26. PubMed ID: 22011666
    [Abstract] [Full Text] [Related]

  • 10. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM.
    Oncotarget; 2016 Jul 26; 7(30):47998-48010. PubMed ID: 27384992
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
    Della Corte CM, Malapelle U, Vigliar E, Pepe F, Troncone G, Ciaramella V, Troiani T, Martinelli E, Belli V, Ciardiello F, Morgillo F.
    Oncotarget; 2017 Apr 04; 8(14):23020-23032. PubMed ID: 28416737
    [Abstract] [Full Text] [Related]

  • 12. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.
    Crit Rev Oncol Hematol; 2014 Feb 04; 89(2):284-99. PubMed ID: 24355409
    [Abstract] [Full Text] [Related]

  • 13. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
    Chen Q, Quan Q, Ding L, Hong X, Zhou N, Liang Y, Wu H.
    Oncotarget; 2015 Sep 22; 6(28):24904-11. PubMed ID: 26172562
    [Abstract] [Full Text] [Related]

  • 14. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
    Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M.
    J Thorac Oncol; 2011 Dec 22; 6(12):2011-7. PubMed ID: 22052230
    [Abstract] [Full Text] [Related]

  • 15. Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
    Moreira-Leite FF, Harrison LR, Mironov A, Roberts RA, Dive C.
    J Thorac Oncol; 2010 Jun 22; 5(6):765-77. PubMed ID: 20421816
    [Abstract] [Full Text] [Related]

  • 16. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
    Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S.
    Clin Cancer Res; 2008 Nov 01; 14(21):7060-7. PubMed ID: 18981003
    [Abstract] [Full Text] [Related]

  • 17. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S.
    Clin Cancer Res; 2010 Jan 01; 16(1):174-83. PubMed ID: 20008840
    [Abstract] [Full Text] [Related]

  • 18. [Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].
    Pi C, Zhang YC, Xu CR, Zhou Q.
    Zhonghua Zhong Liu Za Zhi; 2017 Feb 23; 39(2):94-97. PubMed ID: 28219202
    [Abstract] [Full Text] [Related]

  • 19. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
    Takeuchi S, Yano S.
    Respir Investig; 2014 Nov 23; 52(6):348-56. PubMed ID: 25453378
    [Abstract] [Full Text] [Related]

  • 20. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
    Soucheray M, Capelletti M, Pulido I, Kuang Y, Paweletz CP, Becker JH, Kikuchi E, Xu C, Patel TB, Al-Shahrour F, Carretero J, Wong KK, Jänne PA, Shapiro GI, Shimamura T.
    Cancer Res; 2015 Oct 15; 75(20):4372-83. PubMed ID: 26282169
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.